ImmunityBio: Moving The Needle

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio. It has been roughly four months since my last ImmunityBio (NASDAQ: IBRX ) article , where I discussed ANKTIVA's (N-803) commercial launch for BCG-unresponsive non-muscle invasive bladder cancer. It appeared that ImmunityBio had positioned ANKTIVA for r ...